Teva R&D Chief Eric Hughes to Leave; David Gardiner Named Transition Lead
Teva announced on November 18 that Dr. Eric Hughes, its executive vice president of global research and development and chief medical officer, has decided to leave after accepting an offer outside the company. Hughes will remain with the Israeli pharmaceutical company over the coming months to help manage the handover. Dr. David Gardiner, who heads innovative medicines and clinical development, takes over immediately as R&D transition lead. He will report directly to president and chief executive Richard Francis until a permanent successor is appointed. Francis credited Hughes with helping reshape the research organization and strengthen its pipeline and capabilities. Francis said, “Our strategy, priorities and expectations have not changed…” Hughes said he was proud of the research organization’s achievements and the team it had assembled, and thanked his colleagues. The company presented its pipeline and research capabilities at its R&D Day the previous week. At that November 11 event, Teva outlined its ambition to reach $6–7 billion in annual innovative-medicines revenue by 2030. It said revenue from those medicines had more than doubled since the launch of its Pivot to Growth strategy in 2023. Teva is beginning a comprehensive search for Hughes’s permanent successor immediately.

Commentary